Hypopharyngeal Carcinoma
Conditions
Keywords
Metastatic Neck Nodes, Induction Chemotherapy, Neck Dissection
Brief summary
This is a multi-center, multidisciplinary, open-label, randomized controlled prospective clinical study.
Detailed description
Hypopharyngeal squamous cell carcinoma (HPSCC) is prone to have regional metastasis, which is an established negative prognostic factor. Especially for N2/3 patients whose metastatic neck nodes are bulky and have multiple or extracapsular spreads, their survival outcome is even worse. Therefore, it is vital for clinicians to select proper treatment and further improve the prognosis of N2/3 HPSCC patients. The aim of this randomized controlled prospective study is to explore the suitable treatment strategy of metastatic neck nodes in N2/3 HPSCC. This study will enroll a total of 111 HPSCC patients, who are clinically classified as T1/2 N2/3 M0 stage and initially treated with surgery (group 1) or induction chemotherapy (group 2). For patients with the regional response of PR\<50%/SD/PD after induction chemotherapy, their following treatment will be surgery for both the primary and regional sites. For patients with the regional response of CR/PR≥50%, the following treatment will be concomitant chemoradiotherapy for both the primary and regional sites.
Interventions
DRUGDocetaxel
60 mg/m2 i.v. day 1
DRUGCisplatin
60 mg/m2 i.v. day 1-3
DRUGCapecitabine
750 mg/m2 po bid day 1-14
RADIATIONConcomitant chemoradiotherapy
Radiotherapy: using intensity-modulated radiation therapy (IMRT) Gross tumor volume (GTV) for primary tumor: 66-70 Gy in total, 2.0\ 2.2 Gy per day, 5 days per week Clinical target volume (CTV) for lesions closely related to the primary lesion and metastatic lymph nodes: 65\ 70 Gy in total, 1.7\ 2.0 Gy per day, 5 days per week Prophylactic irradiation for sites of suspected subclinical spread: 50\ 60 Gy in total, 1.7\ 2.0 Gy per day, 5 days per week Concurrent chemotherapy: cisplatin 80 mg/m2 on days 1-3 every 3 weeks.
PROCEDURESurgery
Neck dissection and primary tumor resection
Sponsors
Shandong Provincial Hospital
Harbin Medical University Third Affiliated Hospital
Eye & ENT Hospital of Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Able to understand and willing to sign a written informed consent document. 2. Age ≥ 18 and ≤ 75 years. 3. Male or female. 4. Karnofsky physical status (KPS): ≥ 80 5. Hepatic function, renal function and normal blood test. Hepatic function: Alanine aminotransferase (ALT) ≤ 2.5 upper limit of normal, Aspartate aminotransferase (AST) ≤ 2.5 upper limit of normal. Serum total bilirubin ≤ 1.5 upper limit of normal. Kidney function: Serum creatinine \< upper limit of normal value and creatinine clearance rate \> 60 ml/(min\*1.73m2) (Cockcroft-Gault formula). Blood test: neutrophil (Neu) ≥ 1.5×109/L, platelet (PLT) ≥ 100×109/L, hemoglobin (HGB) ≥ 90 g/L. 6. Pathologically diagnosed with squamous cell carcinoma of the hypopharynx. 7. After clinical and radiographic evaluations, clinically classified as T1/2 N2/3 M0 stage according to American Joint Committee on Cancer (AJCC, eighth edition). 8. Resectable regional metastatic lesion (incompletely tumor- wrapped carotid vascular). 9. Assessable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.1). 10. Radical treatment intent. 11. Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients who do not have fertility (ie meet at least one of the following criteria): Have undergone hysterectomy and/or bilateral oophorectomy with archival records, medically confirmed ovarian function decline; In postmenopausal state. It is defined as: At least 12 months of continuous menstruation without other pathological or physiological reasons, and the status confirmed by serum follicle stimulating hormone (FSH) levels is consistent with postmenopausal status. 12. Good compliance.
Exclusion criteria
1. Distant metastatic disease 2. Have a history of other cancers or coinstantaneous second primary tumor 3. Previous treatment for the primary tumor, including radiotherapy, surgery except biopsy operation, chemotherapy, immunotherapy and biological targeted therapy. 4. Patients who have participated in other clinical trials within 1 month before the test. 5. Patients estimated to have poor tolerance to induction chemotherapy. 6. The investigator believes that it is inappropriate for individuals to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \[within the past year\] or active suicidal ideation or behavior). 7. Palliative treatment intent. 8. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival rate | 3 years | The proportion of patients with disease progress or death due to any reasons. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local control | 3 years | The proportion of patients with local recurrence. |
| Regional control | 3 years | The proportion of patients with regional recurrence. |
| Overall survival rate | 3 years | The proportion of dead patients due to any reasons. |
| Quality of life (UW-QOL V4.0) | 3 years | Evaluated by University of Washington Quality of Life Questionnaire (UW-QOL) V4.0. |
| Adverse events | 3 years | Evaluated by the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) V5.0. |
| Metastasis-free survival | 3 years | The proportion of patients with distant metastasis. |
Countries
China
Contacts
Primary ContactFeiran Li
Outcome results
None listed